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ABSTRACT
Objective: This study aimed to ascertain the effectiveness of combination treatment with propolis and artemisinin-based combination therapy (ACT) 
in avoiding further resistance to ACT.
Methods: A total of 35 mice were injected with Plasmodium berghei and divided into six equal groups: No treatment (negative control), ACT alone 
(positive control), 75-mg propolis/kg body weight (BW), 150-mg propolis/kg BW, ACT with 75-mg propolis/kg BW, and ACT with 150-mg propolis/
kg BW. After 7 days of therapy, parasite density was calculated using a thin blood smear.
Results: Parasite density significantly declined after combination treatment with ACT and 150-mg propolis/kg BW.
Conclusion: Therapy with propolis alone showed no inhibitory effect on parasites, although its 150-mg/kg-BW dose was effective as an ACT adjuvant 
malaria therapy in mice.
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INTRODUCTION
Malaria is a common disease in many parts of the world. In 2015, 
the number of malaria cases reached 214 million worldwide, 
with 438,000 related deaths. Africa has the highest prevalence of 
malaria (88%) followed by Southeast Asia (10%) and the Eastern 
Mediterranean region (2%). In 2014, 30,000,000 cases of high 
transmission malaria with >1 case per 1000 population and 
36,500,000 cases of the cases of low transmission malaria were 
reported in Indonesia. Despite this high number of cases, the global 
malaria burden is decreasing; the malaria incidence rate declined to 
37% in 2015 from that in 2000 [1,2].
Several drugs are currently used to treat malaria infections. However, 
in some regions, Plasmodium has developed resistance to some drugs, 
making some therapies no longer effective. Resistance to artemisinin, 
sulfadoxine/pyrimethamine, mefloquine, chloroquine, and several 
other drugs is common in most parts of Africa and throughout most 
of Southeast Asia [3]. At present, artemisinin-based combination 
therapy (ACT) is used as the first-line treatment for malarial infections. 
Combination therapies are generally administered to improve the 
efficacy of resistant drugs.
In addition to using a combination of chemical drugs, antimalarial 
therapy is now developed using herbal ingredients mainly from 
the African region. Some plants, such as Parkia biglobosa, Tithonia 
diversifolia, and Nauclea latifolia, contain compounds with antimalarial 
activity in their roots, leaves, or stems. In addition, animals and animal 
products, including Malus domestica bees and bee products such as 
honey and propolis, have been investigated for antimalarial activity [4]. 
In a previous study, the decrease in parasitemia levels (PL) was studied 
in mice using a combination of peg earth and chloroquine; the results 
showed no significant decrease in parasitemia after therapy [5]. 
Syamsudin et al. showed that in Plasmodium-infected mice, propolis 
has an immunomodulatory effect, leading to enhanced immunity and 
improved survival [6].
This study aimed to develop antimalarial therapy using a combination of 
ACT and propolis, which is easily found in Indonesia. The combination 
of ACT with propolis is expected to reduce the PL in the study subjects, 
which can then be used to effectively treat malaria.
METHODS
This experimental study was conducted at the Animal Laboratory 
of Puslitbangkes, Jakarta, from April to December 2016. The study 
protocol had been approved by the ethics committee of the Faculty 
of Medicine, Universitas Indonesia. The study population included 35 
healthy 3–4-month-old mice (Mus musculus; weight: 21–30 g) that were 
maintained at Puslitbangkes, Ministry of Health in cages containing five 
mice each. Mice that did not develop parasitemia and those that died 
during the study were excluded from the study. Mice were fed regularly 
with pellets and were exposed to natural light-dark cycles. The 35 mice 
were divided into seven treatment groups (n=5 per treatment):
a. Healthy (without any treatment): Five healthy mice that were not 
given parasites.
b. Control (+): Five mice injected with 0.2 ml of parasites and given 
49.3-mg ACT/kg body weight (BW).
c.	 Control	(−):	Five	mice	injected	with	0.2	ml	of	parasites	without	any	
treatment.
d. Treatment 1 (propolis 1): Five mice injected with 0.2 ml of parasites 
and treated with 75-mg propolis/kg BW.
e. Treatment 2 (propolis 2): Five mice injected with 0.2 ml of parasites 
and treated with 150-mg propolis/kg BW.
f. Treatment 3 (combo 1): Five mice injected with 0.2 ml of parasites 
and treated with 49.3-mg ACT/kg BW+75-mg propolis/kg BW.
g. Treatment 4 (combo 2): Five mice injected with 0.2 ml of parasites 
and treated with 49.3-mg ACT/kg BW+150-mg propolis/kg BW.
Plasmodium berghei was obtained from the parasitology laboratory, 
Faculty of Medicine, Universitas Indonesia, and incubated in nitrogen 
tubes. The parasites were injected into the mice. Once the PL reached 
1%, 0.2 ml of parasites was injected intraperitoneally to each group. 
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All groups of mice, other than the healthy control group, were injected 
with parasites on day 0 (D0) and the therapies were continued orally 
accordingly to group allotment from D1 to D3. The therapy was stopped 
on day 4, but the blood sampling was performed until D7. On D8, the 
mice were euthanized by cervical dislocation. Mouse blood samples 
from D1 to D7 were taken from the tail veins. For this purpose, blood 
was dripped onto preparatory glass, and the tail was pressed against 
the wound until the bleeding stopped. The place of blood collection was 
the same each day.
Thin blood swabs were used for mouse blood preparations and were 
stained with 10% Giemsa dye. The PL was counted per 1000 erythrocytes. 




   





The Kruskal–Wallis was used as a non-parametric test and Mann–
Whitney U-tests was used as a post hoc test for comparisons. Data were 
analyzed using the SPSS v.20 program.
RESULTS
The average PLs of each group of mice were calculated (Fig. 1). Although 
the study was conducted up to D7, data of only up to D4 were used for 
analysis as it was consistent with the 4-day suppressive test theory. The 
PLs	of	 the	C	 (−),	propolis	1,	and	propolis	2	groups	were	significantly	
different from those of the C (+), combo 1, and combo 2 groups. The C 
(−)	group	experienced	a	continuous	increase	in	PLs	up	to	48.4%	on	D4.
The propolis 1 and propolis 2 groups had similar patterns of changes in 
PLs (Table	1).	In	contrast	to	the	C	(−),	propolis	1	and	propolis	2	groups	
showed 3.1% and 3.4% decrease in PLs on D4. The C (+), combo 1, and 
combo 2 groups exhibited low PLs (<2.2%) until the end of therapy. An 
increase in PLs by 1.2%, 1.5%, and 0.5% was observed in D1 in the C 
(+), combo 1, and combo 2 group, respectively.
The 4-day suppression test used the average data of PLs from D0 to D4 
as	a	peak	data.	The	C	(−)	group	showed	the	highest	PLs	on	D4	(55.3%)	
followed by propolis 1 (43.6%) and propolis 2 (31.2%). By contrast, 
the C (+), combo 1, and combo 2 groups showed very low PLs of 0.6%, 
0.3%, and 0%, respectively, on D4.
D0–D4 PLs were analyzed using SPSS v.20. The data were not significant 
(p<0.05) according to the non-parametric Kruskal–Wallis test (Table 2). The 
Mann–Whitney U-test was used to obtain the results are shown in Table 3.
According to the Mann–Whitney U-test, the C (+) and combo 1 groups, 
propolis 1 and propolis 2 groups, and combo 1 and combo 2 groups 
were not significantly different from each other.
The growth inhibition (GI) of the parasites was calculated by the 
previously mentioned formula (Fig. 2). The GI was calculated by 
the	ratio	PL	of	C	(−)	and	to	those	of	the	treated	groups	to	reveal	how	
effectively the different treatments inhibited parasite growth up to D4.
In the propolis 1 and propolis 2 groups, a decrease in GI was observed 
from D1 (52.64% and 58.87% PLs, respectively) to D2 (1.59% and 
23.41% PLs, respectively). GI increased from D3 to D4 (from 7.96% to 
43.63%). In D7, the C (+) group, GI increased up to 99.90%. The combo 
1 and combo 2 groups showed results similar to those observed in the 
C (+) group. From D0 to D3, the combo 2 group showed the highest 
increase in GI followed by the C (+) and combo 1 groups. On D4, the 
combo 1 group showed a GI of 99.20%, which was higher than that of 
98.88% in the C (+) group.
DISCUSSION
Propolis contains a variety of chemical compounds with various 
pharmacological effects including antioxidant, anti-inflammatory, 
antibacterial, anticancer, antifungal, and antiviral effects [7]. In 
accordance with the 4-day suppression test theory, we found the 
lowest PL on D4 in the groups receiving combination therapy of 
150-mg propolis/kg BW and ACT, combination therapy of 75-mg 
propolis/kg BW and ACT, ACT alone, only 150-mg propolis/kg BW, only 
75-mg propolis/kg BW, and no treatment. In addition, the combination 
of 150-mg propolis/kg BW and ACT showed the highest GI among all 
groups every day after D2.
GI was likely caused by the activity of flavonoids and hydroxycinnamic 
acid in propolis, which are powerful antioxidants that increase 
immunity [8,9]. Enhanced immunity likely improves the ability of ACT 
to damage the parasites circulating in the blood. Therefore, propolis can 
serve as an adjunctive therapy for improving the effectiveness of ACT as 
a standard malaria drug.
However, propolis therapy alone at doses of 75 and 150 mg/kg BW 
did not show good results for use as a single malaria therapy. On D4, a 
decrease in PLs was observed in both single propolis therapy groups, 
whereas an increase was observed in the negative controls. This finding 
is consistent with that of a study by Syamsudin et al. who found a 
decrease in PL on D4 after treatment with propolis at doses of 25, 50, 
Fig. 1: Average parasitemia levels of D0–D4
Table 1: PLs and GI D0–D4 (%)
Group D0 D1 D2 D3 D4
PL PL GI PL GI PL GI PL GI
C (+) 0.5 1.7 83.77 1.0 96.69 0.5 99.01 0.6 98.88
C	(−) 0.8 10.6 - 29.0 - 48.4 - 55.3 -
Propolis 1 0.84 5.0 52.64 28.5 1.59 46.7 3.51 43.6 7.96
Propolis 2 0.8 4.4 58.87 22.2 23.41 34.6 28.49 31.2 43.63
Combo 1 0.5 2.1 79.81 0.6 91.57 0.6 98.80 0.3 99.20
Combo 2 0.6 1.0 90.57 0.6 93.44 0.4 99.09 0.0 100.0
PLs: Parasitemia levels, GI: Growth inhibition
Table 2: Kruskal–Wallis test results
Days of 
Treatment
Dosage n Brinkmann index p value
H4–H0 C (+) 5 14.70	(−0.10–0.40) <0.001
C	(−) 5 33.00 (49.00–69.10)
Propolis 1 5 27.00 (39.90–45.10)
Propolis 2 5 24.00 (6.60–44.65)
Combo 1 5 9.90	(−0.60–0.00)
Combo 2 5 3.90	(−0.80–0.10)
Total 35
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treatment groups showed increase in parasite replication. The anti-
inflammatory effects of substances found in propolis, such as chrysin, 
gallangin, and m-coumaric acid, can suppress the immune response 
of mice resulting in increased parasite replication [9]. Differences 
between studies may be due to the varying levels of substances in 
propolis depending on the site of propolis production and the bees that 
produce it. The commercially obtained propolis is usually extracted 
using ethanol [10]. The use of commercial propolis from different 
geographical locations is likely to contain different compounds with 
pharmacological properties.
In general, combination therapy of propolis and ACT caused a 
higher decrease of PLs than the ACT alone. Thus, propolis at a dose 
of 150 mg/kg BW could be used as an additional therapy with ACT 
for malaria in mice. However, propolis administration alone could 
stimulate parasite replication. Further studies using human subjects 
are warranted to validate the use of this combination for treating 
human malaria cases.
CONCLUSION
The administration of propolis alone to experimental mice infected 
with P. berghei was not effective in reducing PLs compared with 
the combination of propolis and ACT. PLs after treatment with a 
combination of propolis and ACT tended to decrease, with GI higher 
than that by treatment with propolis or ACT alone.
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Fig. 2: Growth inhibition
and 100 mg/kg BW. However, from D1 to D3, no decrease was observed 
in PLs any of the single propolis therapy group administered [6].
During Plasmodium infection, mice develop antibodies according 
to their infection phase [7]. Syamsudin et al. showed that propolis 
treatment continuously increased the titer of IgG antibodies in 
mice from D1 to D4 [6]. On D4, a large increase was observed in GI 
compared with the increase on D3. However, this increase was not 
linear because GI on D1 was the highest. On D5–D7, single propolis 
Table 3: Mann–Whitney U‑test results
Groups of Treatment Asymptotic 
significance (two‑tailed)
C (+)
C	(−) 0.009*
Propolis 1 0.009*
Propolis 2 0.009*
Combo 1 0.147
Combo 2 0.011*
C	(−)
Propolis 1 0.009*
Propolis 2 0.009*
Combo 1 0.008*
Combo 2 0.009*
Propolis 1
Propolis 2 0.116
Combo 1 0.008*
Combo 2 0.009*
Propolis 2
Combo 1 0.008*
Combo 2 0.009*
Combo 1
Combo 2 0.070*
*p<0.05
